Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Teva Japan Pres. Kikushige to Double as Head of Taisho Pharma
November 28, 2013
- Teva Pharma Japan to Temporarily Suspend Supply of Elsamet Combination Tablets
November 28, 2013
- Azilva Tops Physician “Mind Share” Ranking in GP, HP Markets in October: New Survey
November 27, 2013
- Sanofi to Revamp Sales Organization, 5 Units to Come Under Direct Control of President
November 27, 2013
- Santen’s Anti-Allergic Eye Drops Alesion Goes on Sale
November 27, 2013
- Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
- CHMP Recommends Approval of Otsuka’s Delamanid for Treatment of MDR-TB
November 27, 2013
- IFN-Free Hepatitis C Drugs Could Hit Pharmacy Shelves in 2014, New Option for Elderly Patients
November 26, 2013
- Alfresa Pharma Gets Additional Indication for Anafranil
November 26, 2013
- Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
- GSK’s Paxil Granted Japan’s 1st PTSD Indication
November 26, 2013
- Japan’s 1st Acetaminophen IV Injection Now Available
November 26, 2013
- Chugai’s Avastin Approved for Ovarian Cancer Treatment
November 25, 2013
- AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
- Preminent Generics of 30-Plus Firms Likely to Carry “Losarhyd” Brand; Unified Trade Names Logged for 4 More Combination Generics
November 25, 2013
- Kyowa Kirin Launches New PIII Trial for Istradefylline
November 25, 2013
- ASKA Pharmaceutical Plans to Launch Generic Version of Takeda’s Leuplin, Aims for 20% Market Share
November 25, 2013
- Once-Monthly Injectable Abilify Maintena Approved in Europe: Otsuka
November 25, 2013
- Domestic Ethical Drug Market Estimated to Reach 9,617.7 Billion Yen in 2020: Fuji Keizai
November 22, 2013
- Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…